Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria: (Applicable to both parts)~1. Male/females of 40 to 65 years of age~2. Body Mass Index (BMI) between 18.5 and 35 kg/m2~3. Able to provide written Informed Consent~4. Able to follow verbal and written study directions~5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.~6. Able to maintain consistent diet and lifestyle habits throughout the study~7. Male and female subjects must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study~8. Willing to consume assigned supplement (NMN or placebo) for 2 months~Exclusion Criteria: (Applicable to both parts).~1. Participants on current use of prescription or over-the-counter nicotinic acid~2. Use of statin drugs~3. Having used any tobacco product or used a recreational drug in the past 6 months~4. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator~5. Documented presence of atherosclerotic disease and/or cardiopulmonary disease~6. History of drug or alcohol abuse~7. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements~8. Unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the study start~9. Participating in or planning to begin a weight loss diet during the study period,~10. Lifestyle or schedule incompatible with the study protocol~11. Known hypersensitivity to any form of niacin used during the study~12. Women with positive result for Urine Pregnancy Test or gestation period or breastfeeding~13. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.~14. Currently, or within the past 30 days, enrolled in a different clinical investigation~15. Inability to provide a venous blood sample~16. Unable or unwilling to provide written informed consent for participation in study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm A = 300 mg NMN supplement (n = 20) (Type: ACTIVE_COMPARATOR): Subjects who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
- Arm B = Placebo 300 mg (n=07) (Type: PLACEBO_COMPARATOR): Subjects who are assigned to 300 mg arm (placebo) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
- Arm C = NMN Supplement 600 mg (n= 20) (Type: ACTIVE_COMPARATOR): Subjects who are assigned to 600 mg arm (NMN) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
- Arm D = Placebo 600 mg (n=07) (Type: PLACEBO_COMPARATOR): Subjects who are assigned to 600 mg arm (Placebo) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
- Arm E = NMN Supplement 900 mg (n=10) (Type: ACTIVE_COMPARATOR): Subjects who are assigned to 900 mg arm (NMN) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
- Arm F = Placebo 900 mg (n=06) (Type: PLACEBO_COMPARATOR): Subjects who are assigned to 900 mg arm (Placebo) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).